Fig. 4: Overall survival (OS) and progression-free survival (PFS) from start of first line immune checkpoint inhibitor (ICI) therapy amongst ICI treated patients (n = 217).
From: PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome
A High PD-1 RNA expression is predictive of longer OS after ICI therapy, p = 0.0032. P value was derived from log-rank test. Patients discontinued ICI at the time of progression. Red line represents low to moderate PD-1 expression. Teal line represents high PD-1 expression. B High PD-1 RNA expression is predictive of longer PFS after ICI therapy, p = 0.039. P value was derived from log-rank test. Median PFS was 4.5 and 6.2 months for moderate/low and high PD-1 expressors, respectively. In the moderate/low PD-1 expressor group, 25% of patients remained on therapy at 10.0 months; in the high PD-1 expressor group, 25% of patients remained on therapy at 14.5 months.
